{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saxagliptin-Metformin+XR", "query": { "intervention": "Saxagliptin-Metformin XR" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saxagliptin-Metformin+XR&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T01:01:11.174Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00683657", "title": "Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "77 Years", "sex": "ALL", "summary": "18 Years to 77 Years" }, "enrollment_count": 93, "start_date": "2008-07", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2015-06-01", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Escondido, California • Irvine, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00683657" }, { "nct_id": "NCT01874080", "title": "Bioequivalence Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin/Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 56, "start_date": "2013-06", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-04-23", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874080" }, { "nct_id": "NCT01267448", "title": "Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus Type 2", "Hyperglycemia" ], "interventions": [ { "name": "Glipizide XL", "type": "DRUG" }, { "name": "Saxagliptin + Metformin XR", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cook County Health", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2014-09-09", "completion_date": "2015-07-25", "has_results": false, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01267448" }, { "nct_id": "NCT03169959", "title": "A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "2.5 mg Saxagliptin tablet", "type": "DRUG" }, { "name": "5 mg dapagliflozin / 1000 mg metformin XR tablet", "type": "DRUG" }, { "name": "Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR", "type": "DRUG" }, { "name": "5 mg saxagliptin", "type": "DRUG" }, { "name": "10 mg dapagliflozin / 1000 mg metformin XR tablet", "type": "DRUG" }, { "name": "Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 85, "start_date": "2017-05-29", "completion_date": "2017-08-03", "has_results": false, "last_update_posted_date": "2017-08-14", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03169959" }, { "nct_id": "NCT02022007", "title": "Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polycystic Ovary Syndrome", "Disorder of Glucose Regulation" ], "interventions": [ { "name": "Metformin XR", "type": "DRUG" }, { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Saxagliptin-Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Woman's", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "FEMALE", "summary": "18 Years to 42 Years · Female only" }, "enrollment_count": 38, "start_date": "2014-03", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02022007" }, { "nct_id": "NCT01192139", "title": "Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "saxagliptin", "type": "DRUG" }, { "name": "metformin XR", "type": "DRUG" }, { "name": "saxagliptin + metformin XR (FDC tablet)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2009-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2015-05-21", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192139" }, { "nct_id": "NCT01525225", "title": "Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Metformin immediate release (IR)", "type": "DRUG" }, { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" }, { "name": "Saxagliptin/Metformin XR FDC", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 4, "start_date": "2012-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2015-06-22", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525225" }, { "nct_id": "NCT01441869", "title": "Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin" ], "interventions": [ { "name": "Onglyza (saxagliptin)", "type": "DRUG" }, { "name": "Diabex", "type": "DRUG" }, { "name": "5-mg saxagliptin/1000 mg metformin", "type": "DRUG" }, { "name": "5-mg saxagliptin/500 mg metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2011-10", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-02-08", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01441869" }, { "nct_id": "NCT00960076", "title": "An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 282, "start_date": "2009-08", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2011-09-27", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 22, "location_summary": "Jonesboro, Arkansas • Anaheim, California • Fountain Valley, California + 19 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960076" }, { "nct_id": "NCT01606007", "title": "Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo matching with Dapagliflozin", "type": "DRUG" }, { "name": "Placebo matching with Saxagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1282, "start_date": "2012-07", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-09-22T01:01:11.174Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606007" } ] }